Research teams, sponsors and CROs comparing data collection for clinical trials, from focused participant-centered studies to complex multi-site protocols.
Scope Dedicated EDC systems and participant-centered clinical-trial data collection are compared by their documented capabilities. Whether a participant-centered platform also needs a dedicated EDC depends on in-visit data entry, clinical queries, coding, verification and database-management requirements, rather than study size or trial phase alone.
These notes describe the products in the EDC guide.
Castor
Best for
Academic groups, biotechs and device teams running investigator-initiated or mid-size studies who want to build studies themselves.
What to consider
Castor has a large published study footprint and strong certifications, and teams can build studies without vendor help. It offers fewer native modules than the enterprise suites, and Everest Group placed it as a Major Contender rather than a Leader in 2024.
Sponsors and CROs already on Veeva's clinical platform who want EDC, RTSM, eCOA and CTMS from the same vendor.
What to consider
Veeva EDC documents mid-study changes and connected clinical applications, and Veeva says eight of the top 20 biopharmas have switched to it. Veeva publishes no study count and no prices.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Castor vs Veeva EDC (EDC): category feature evidence and sources. Products are not ranked.
Category feature
Castor
Veeva EDC
Track record in regulated multi-site trialsFeature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Castor
Extended support
Castor reports more than 31,900 studies with 9.5 million participants in 171 countries, but its pages give no evidence of global Phase III programs.
Study build and mid-study changesFeature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Castor
Supported
Castor offers self-service build with a low-code eCRF builder and reusable templates, and says forms can be edited mid-study with audit trails and separate test environments, without a no-downtime claim.
Self-build and audited mid-study edits are stated; uninterrupted live use is not claimed.
Veeva EDC
Supported
Veeva's white paper states that amendments add new elements without bringing the system down or migrating data, with only a brief casebook lockout while a change deploys.
Trial standards and ISO certification are listed; public certificate or report access is not established.
Veeva EDC
Supported
Veeva's trust page lists ISO 27001, ISO 27017, ISO 27018 and a SOC 2 Type II report, and its EDC help docs state that Veeva EDC eSignature meets 21 CFR Part 11.
An API and FHIR alignment are stated; named CDISC-format exchange is not established.
Veeva EDC
Supported
Veeva documents a versioned CDMS API for study data, definitions and coding requests with a data model similar to CDISC ODM, but its ODM casebook export is a legacy feature.